The role of chemotherapy in advanced oral cavity cancer

Caballero, Miguel; Grau, Juan J.; Casellas, Sandra; Bernal‐Sprekelsen, Manuel; Blanch, José Luís

doi:10.1016/s2173-5735(09)70140-1

Cited by 3 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sanjiv et al 3 for Cal 27 on the 12th day, mice were randomly divided into four groups. The first group received vehicle, the second group was treated with 40 mg/kg body weight BO-1090, the third group received 60 mg/kg BO-1090, and the fourth group was treated with 4 mg/kg cisplatin.…”

Section: Cancer Therapymentioning

confidence: 99%

“…2 The treatments of oral cancer include surgery, radiation or chemotherapy, depending on the stage and nature of the tumor. 3,4 Unfortunately, only marginal improvement is seen in many patients, and a complete cure is often not achieved. Half of the patients diagnosed with oral cancer succumb to death within 5 years, and for those who survive, the quality of life remains poor.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The novel DNA alkylating agent BO‐1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models

Sanjiv

Suman

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

Oral cancer is the fourth-most common cause of death in males and overall the sixth-most common cause of cancer death in Taiwan. Surgery, radiotherapy and chemotherapy combined with other therapies are the most common treatments for oral cavity cancer. Although cisplatin, 5-fluorouracil and docetaxel are commonly used clinically, there is no drug specific for oral cavity cancer. Here, we demonstrated that derivatives of 3a-aza-cyclopenta[a]indene, a class of newly synthesized alkylating agents, may be drugs more specific for oral cancer based on its potent in vitro cytotoxicity to oral cancer cells and on in vivo xenografts. Among them, BO-1090, bis(hydroxymethyl)-3a-aza-cyclopenta[a]indene derivative, targeted DNA for its cytotoxic effects as shown by inhibition of DNA synthesis (bromodeoxyuridine-based DNA synthesis assay), induction of DNA crosslinking (alkaline gel shift assay), and induction of DNA single-stranded breaks (Comet assay) and double-stranded breaks (c-H2AX focus formation). Following DNA damage, BO-1090 induced G1/S-phase arrest and apoptosis in oral cancer cell lines. The therapeutic potential of BO-1090 was tested in mice that received a xenograft of oral cavity cancer cell lines (SAS or Cal 27 cells). Intravenous injection of BO-1090 significantly suppressed tumor growth in comparison to control mice. BO-1090 also significantly reduced the tumor burden in orthotopic mouse models using SAS cells. There was no significant adverse effect of BO-1090 treatment with this dosage based on whole blood count, biochemical enzyme profiles in plasma and histopathology of various organs in mouse. Taken together, our current results demonstrate that B0-1090 may have potential as a treatment for oral cavity cancer.Oral cavity cancer involving the lesions occurred in the tongue, oropharynx and floor of the mouth is a prevalent type of cancer in developing countries such as India, Pakistan, Bangladesh and Taiwan. 1 In south-central Asia, it is the third-most common cancer, with an average incidence rate of 1 to 10 per 100,000 people. The incidence of oral cancer is also increasing in developed countries. 2 The treatments of oral cancer include surgery, radiation or chemotherapy, depending on the stage and nature of the tumor. 3,4 Unfortunately, only marginal improvement is seen in many patients, and a complete cure is often not achieved. Half of the patients diagnosed with oral cancer succumb to death within 5 years, and for those who survive, the quality of life remains poor. 1 Thus, development of a drug specific for oral cavity cancer is needed so that substantial improvement in treatment can be achieved.The cytotoxic and antitumor properties of alkylating agents are due to their ability to covalently bind to DNA. There are two types of DNA alkylating agents, monofunctional and bifunctional agents. Monofunctional alkylating agents mainly damage DNA by forming methylated adducts, whereas the damage induced by bifunctional alkylating agents includes monoadducts, intrastrand crosslinks and interstrand crossli...

show abstract

Section: Cancer Therapymentioning

confidence: 99%

mentioning

confidence: 99%

The novel DNA alkylating agent BO‐1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models

Sanjiv

Suman

et al. 2011

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…De esta terapéutica deriva la aparición de complicaciones en tejidos cuya configuración celular es de recambio continuo y permanente, tales como el epitelio o mucosas de recubrimiento [36][37][38][39][40][41][42]. El tiempo de administración depende del tipo, las dimensiones del tumor, las toxicidades previstas de los fármacos y el tiempo necesario para recuperarse de esas toxicidades [11,43,44].…”

Section: El Tratamiento Del Cáncer Y La Cavidad Oralunclassified

Condiciones estomatológicas en pacientes con cáncer durante y posterior al tratamiento antineoplásico: revisión narrativa de la literatura

2017

View full text Add to dashboard Cite

Introducción: las consecuencias de los tratamientos antineoplásicos,traen consigo implicaciones bucales y empeoramiento de otras lesiones ya prestablecidas al diagnóstico oncológico, indistintamente del órgano afectado por eltumor. Complicaciones tales como las mucositis orales, candidiasis orales, trismo,xerostomía, caries, entre otras lesiones, suelen suceder con frecuencia, y puedenser transitorias en el curso de la aplicación de terapéuticas para el cáncer, como,por ejemplo, quimioterapia y radioterapia; otras prevalecen posterior a la finalizaciónde estas terapéuticas. Métodos: se realizó una revisión narrativa de la literaturaque mostró la unificación de criterios que involucran la descripción de los patronesclínicos de cada una de las complicaciones orales por el tratamiento oncológico,en relación con cánceres de diferentes localizaciones. Se efectuó una búsqueda bibliográfica en idioma inglés y español usando los siguientes descriptores: “lesiones,boca, cáncer, quimioterapia, radioterapia, complicaciones orales, antes y después,lesions, mouth cancer, chemotherapy, radiotherapy, oral complications, after y before, para las base de datos global Pubmed y Scielo. En esta se seleccionaron 100 artículos publicados en un período de 15 años. Resultados: la mayoría de autores consultados coinciden en afirmar que una amplia gama de tumores malignos tienden a mostrar afectación secundaria en lugares como la cavidad oral, en su mayoría porel tratamiento oncológico instaurado, sin distinción de tipo tumoral y localizacióndel mismo. Conclusiones: la cavidad bucal sigue siendo susceptible a la presenciade estos efectos, los cuales se identifican como eventos citotóxicos sistémicos entejidos de recambio rápido, como lo es la mucosa bucal.

show abstract

“…Induction QTP can extend survival from 8% to 20% and concomitant adjuvant chemo-radiotherapy can prolong survival up to 16%. QTP consists of the administration of cytotoxic drugs that are capable of destroying and inhibiting the growth and reproduction of malignant cells [9]. In head and neck cancers, the most extensively used drugs are bleomycin, cisplatin, methotrexate, 5-fluorouracil, vinblastine and cyclophosphamide [10].…”

Section: Head and Neck Cancermentioning

confidence: 99%

Radiotherapy and Chemotherapy Treatments in Head and Neck Cancer Patients — Protocol for Management Before, During and After RTP

Alvarez¹,

García²,

Padín-Iruegas³

et al. 2015

Updates on Cancer Treatment

View full text Add to dashboard Cite

The role of chemotherapy in advanced oral cavity cancer

Cited by 3 publications

References 23 publications

The novel DNA alkylating agent BO‐1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models

The novel DNA alkylating agent BO‐1090 suppresses the growth of human oral cavity cancer in xenografted and orthotopic mouse models

Condiciones estomatológicas en pacientes con cáncer durante y posterior al tratamiento antineoplásico: revisión narrativa de la literatura

Radiotherapy and Chemotherapy Treatments in Head and Neck Cancer Patients — Protocol for Management Before, During and After RTP

Contact Info

Product

Resources

About